Skip to main content

Table 1 Patients’ demographic and baseline characteristics

From: Diclofenac–hyaluronate conjugate (diclofenac etalhyaluronate) intra-articular injection for hip, ankle, shoulder, and elbow osteoarthritis: a randomized controlled trial

Characteristic Hip N = 90 Ankle N = 60 Shoulder N = 90 Elbow N = 50 Total N = 290
Age, years 59.9 ± 8.9 65.4 ± 11.6 70.2 ± 11.4 61.3 ± 13.0 64.5 ± 11.8
Sex
 Male 10 (11.1) 13 (21.7) 47 (52.2) 37 (74.0) 107 (36.9)
 Female 80 (88.9) 47 (78.3) 43 (47.8) 13 (26.0) 183 (63.1)
BMI, kg/m2 23.43 ± 3.37 24.67 ± 3.54 24.03 ± 3.46 24.32 ± 3.47 24.03 ± 3.46
Duration of current joint pain, weeks 241.8 ± 255.7 188.3 ± 196.1 161.3 ± 186.4 358.5 ± 401.8 225.9 ± 266.0
Classification of OA
 Primary 18 (20.0) 42 (70.0) 69 (76.7) 43 (86.0) 172 (59.3)
 Secondary 72 (80.0) 18 (30.0) 21 (23.3) 7 (14.0) 118 (40.7)
Stage of OAa, n (%)
 Stage A 27 (30.0) 19 (31.7) 53 (58.9) 22 (44.0) 121 (41.7)
 Stage B 63 (70.0) 41 (68.3) 37 (41.1) 28 (56.0) 169 (58.3)
NRS for painb, n (%) 6.94 ± 1.06 7.02 ± 1.06 6.63 ± 1.08 6.69 ± 0.93 6.82 ± 1.05
  1. Data are presented as mean ± standard deviation or n (%)
  2. BMI body mass index, OA osteoarthritis, NRS numerical rating scale
  3. aStage A: Kellgren–Lawrence (KL) grading score for hip OA stage (Early stage); ankle OA stage (Stage 1/ Stage 2); shoulder OA and elbow OA (Grade 2). Stage B: KL grading score for hip OA stage (Advanced stage); ankle OA stage (Stage 3); shoulder OA and elbow OA (Grade 3)
  4. bAverage of 7 days prior to Week 0 by the 0–10 numerical rating scale for pain intensity: 0 indicates no pain, and 10 indicates the worst pain